Clinical trials: SARS-COV-2 Infection
SARS-COV2 Infection, Covid19
Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum
For an antiviral agent to act as an effective biological barrier on nasal mucosal surface, the formulation preferably has to be maintained on the site of action for several hours, and the nasal spray dispenser can be utilized for…
- Trial name
- NCT04916574
- Testing
- Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
- Where
- Estonia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Icosagen Cell Factory
Pneumococcal Infection
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease…
- Trial name
- NCT05158140
- Testing
- V110, V114, mRNA-1273
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, SARS-CoV-2
NOWDx Test for the Detection of Antibodies to COVID-19
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04690413
- Testing
- NOWDx COVID-19 Test
- Where
- 3 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- NOWDiagnostics, Inc.
Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05665153
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bluejay Diagnostics, Inc.
COVID-19
The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
This study is a multi-center, randomized, double blinded, prospective, placebo controlled study. Patients upon diagnosis of COVID-19 (Corona Virus Disease-19) will be eligible to participate in the study.
- Trial name
- NCT04601077
- Testing
- Nitric Oxide lozenges, 30 mg
- Where
- United States
- Volunteers
- 524 people
- Sponsor
- Nitric Oxide Innovations LLC
Covid-19
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
- Trial name
- SOC (NCT04440007)
- Testing
- Abivertinib, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
This is a Phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal STI-9199 in adults and adolescents who are COVID-19 positive with mild to…
- Trial name
- NCT05372783
- Testing
- STI-9199
- Where
- United States
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
COVID-19 Prevention
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
- Trial name
- NCT04908722
- Testing
- Ad26.COV2.S
- Where
- 43 sites in United States, Brazil and 3 more
- Volunteers
- 1,609 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Healthy
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants.
- Trial name
- NCT04590430
- Testing
- HFB30132A
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HiFiBiO Therapeutics
SARS CoV 2 Infection
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
- Trial name
- NCT06234956
- Testing
- BIMERVAX
- Where
- 7 sites in Spain
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
SARS-CoV-2 Infection, Fibrosis Lung
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
The innovative drug Treamid is planned for use in the rehabilitation of patients after COVID-19 pneumonia in a pilot, multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to assess the efficacy and…
- Trial name
- NCT04527354
- Testing
- Treamid
- Where
- 8 sites in Russia
- Volunteers
- 60 people
- Sponsor
- PHARMENTERPRISES LLC
COVID-19
The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 150 mg versus placebo once daily administration with standard of care therapy for 10 days in patients with mild and moderate COVID-19.
- Trial name
- NCT04891302
- Testing
- Clevudine
- Where
- 11 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Bukwang Pharmaceutical
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory…
- Trial name
- NCT06585241
- Testing
- mRNA-1273 Variant-containing Formulation
- Where
- 6 sites in United States
- Volunteers
- 1,144 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.
- Trial name
- NCT04410354
- Testing
- Merimepodib, Remdesivir
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- ViralClear Pharmaceuticals, Inc.
Long COVID
Feasibility of Cannabidiol for the Treatment of Long COVID
This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID.
- Trial name
- NCT04997395
- Testing
- MediCabilis Cannabis sativa 50
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Bod Australia
COVID-19
A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI
This is a first-in-human (FIH), Phase 1b, open-label, dose-escalation, safety trial consisting of 3 dose levels. Subjects will always be treated in cohorts of size 3, with from 3 up to 6 cohorts i.e. 9-18 subjects.
- Trial name
- NCT05348772
- Testing
- AmnioPul-02
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- Amniotics AB
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems
COVID-19
AZD1222 Vaccine for the Prevention of COVID-19
The purpose of this study is to evaluate safety and immunogenicity of AZD1222 for COVID-19 prevention in the Russian Federation
- Trial name
- NCT04540393
- Testing
- AZD1222
- Where
- 4 sites in Russia
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Covid19
SLV213 Treatment in Ambulatory COVID-19 Patients
This Phase 2a trial recruits adult ambulatory patients who have been determined to be COVID-19 positive. The study drug SLV213 will be administered to examine its safety, tolerability and provide assessment of its effect on…
- Trial name
- NCT04843787
- Testing
- SLV213
- Volunteers
- 81 people
- Sponsor
- Kenneth Krantz, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.